



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/805,222-Conf. #9133
				Filing Date	March 22, 2004
				First Named Inventor	Mark R. Burns
				Art Unit	1625
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	22116-00011-US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author ( in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
RD	CA	Tetrahydro- $\beta$ -carboline, Potential Neuroactive Alkaloids, in Chocolate and Cocoa by Tomas Herraiz, J. Agric. Food Chem. 2000, 48, pages 4900-4904			
RD	CB	Glutamate Receptors in the Mammalian Central Nervous System, by Seiji Ozawa et al., Progress in Neurobiology vol. 54, pages. 581-618, 1998			
RD	CC	Glutamate Neurotoxicity and Diseases of the Nervous System, by Dennis Choi, Neuron, vol. 1, pages 623-634, October 1988			
RD	CD	NMDA receptors as targets for drug action in neuropathic pain, by Chris Parsons, European Journal of Pharmacology 429, 2001, pages 71-78			
RD	CE	Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats, by Zofia Rogoz et al., Neuropharmacology 42, 2002, pages 1024-1030			
RD	CF	Modulation of the NMDA Receptor by Polyamines, by Keith Williams, et al., Life Sciences, vol. 48, pages 469-498, 1991			
RD	CG	Characterization of the Effects of Polyamines on [ <sup>125</sup> I] MK-801 Binding to Recombinant N-Methyl-D-Aspartate Receptors, by Terre Sharma et al., The Journal of Pharmacology and Experimental Therapeutics, 1999, pages 1041-1047			
RD	CH	Endogenous indoles as novel polyamine site ligands as the N-methyl-D-aspartate receptor complex, by David Worthen et al., Brain Research 890 2001, pages 343-346			
RD	CI	N <sup>1</sup> -Dansyl-Spermine and N <sup>1</sup> -(n-Octanesulfonyl)-Spermine, Novel Glutamate Receptor Antagonists: Block and Permeation of N-Methyl-D-Aspartate Receptors, by James Chao et al., Molecular Pharmacology, pages 861-871 1997			
RD	CJ	Functional antagonists at the NMDA receptor complex exhibit antidepressant actions, by Ramon Trullas et al., European Journal of Pharmacology 185 1990, pages 1-10			
RD	CK	Potential Antidepressive Properties of Amantadine, Memantine and Bifemelane, Elzbieta Moryl et al., Pharmacology & Toxicology 1993, 72, pages 394-397			
RD	CL	The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT <sub>3</sub> receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner, by G. Rammes et al., Neuroscience Letters 306 2001, pages 81-84			
Examiner Signature	RD			Date Considered	10/13/05

370728

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/805,222-Conf. #9133
				Filing Date	March 22, 2004
				First Named Inventor	Mark R. Burns
				Art Unit	1625
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	22116-00011-US

<input checked="" type="checkbox"/>	CM	Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data, by C.G. Parsons et al., Neuropharmacology, 38, 1999, pages 735-767	
<input checked="" type="checkbox"/>	CN	NMDA Receptor Antagonists and Antidepressant Drugs, by J. Maj, Pharmacological Research, Vol. 25, Supplement 2, 1992	
<input checked="" type="checkbox"/>	CO	Anticonvulsant effects of eliprodil alone or combined with the glycine <sub>B</sub> receptor antagonist L-701,324 or the competitive NMDA antagonist CGP 40116 in the amygdala kindling model in rats, by Piotr Wlaz et al., Neuropharmacology 38, 1999, pages 243-251	
<input checked="" type="checkbox"/>	CP	Synthesis and Resolution of Racemic Eliprodil and Evaluation of the Enantiomers of Eliprodil as NMDA Receptor Antagonists, by Jorg Pabel et al., Bioorganic & Medicinal Chemistry Letters 10, 2000, pages 1377-1380	
<input checked="" type="checkbox"/>	CQ	Affinities of 5-HT Uptake Inhibitors for 5-HT <sub>3</sub> Receptors in Both Binding and Functional Studies, GJ Kilpatrick et al., Brit J. Pharmacol. 1989 98 (suppl.) #17 pages 859	
<input checked="" type="checkbox"/>	CR	The interaction of antidepressant drugs with central and peripheral (enteric) 5-HT <sub>3</sub> and 5-HT <sub>4</sub> receptors, by A. Lucchelli et al., British Journal of Pharmacology 1995, 114, pages 1017-1025	
<input checked="" type="checkbox"/>	CS	Higher-End Serotonin Receptors: 5-HT <sub>5</sub> , 5-HT <sub>6</sub> , and 5-HT <sub>7</sub> , by Richard Glennon, Journal of Medicinal Chemistry, 2003, vol. 46, number 14, pages 2795-2812	
<input checked="" type="checkbox"/>	CT	Molecular, pharmacological and functional diversity of 5-HT receptors, by Daniel Hoyer et al., Pharmacology, Biochemistry and Behavior 71, 2002, pages 533-554	
<input checked="" type="checkbox"/>	CU	Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats, by A. Pilc et al., Neuropharmacology, 43, 2002, pages 181-187	
<input checked="" type="checkbox"/>	CV	Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7, by John Cryan et al., European Journal of Neuroscience, Vol. 17, pages 2409-2417, 2003	
<input checked="" type="checkbox"/>	CW	Solid Phase Synthesis of Heterocyclic Compounds from Linear Peptides: Cyclic Ureas and Thioureas, by Adel Nefzi et al., Tetrahedron Letters, vol. 38, No. 6, pages 931-934, 1997	
<input checked="" type="checkbox"/>	CX	Antidepressants for the new millennium by Phil Skolnick, European Journal of Pharmacology 375, 1999, pages 31-40	
<input checked="" type="checkbox"/>	CY	Mild Oxidative Cleavage of Borane-Amine Adducts from Amide Reductions: Efficient Solution- and Solid Phase Synthesis of N-Alkylamino Acids and Chiral Oligoamines, by Dennis Hall et al., J. Org. Chem. 1999, 64, pages 698-699.	
<input checked="" type="checkbox"/>	CZ	Behavioural Despair in Rats: A New Model Sensitive to Antidepressant Treatments, by Roger Porsolt et al., European Journal of Pharmacology, 47 (1978), pages 379-391	
<input checked="" type="checkbox"/>	CA1	Anxiogenic Effects of Methyl-β-Carboline-3-Carboxylate in a Light/Dark Choice Situation, by Catherine Belzung et al., Pharmacology Biochemistry & Behavior, vol. 28, pages 29-33, 1987	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>R. Desai</i>	Date Considered	10/13/05
--------------------	-----------------	-----------------	----------